Cargando…
Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
BACKGROUND: The purpose of the study was to evaluate the 2-year outcome and predictive factors of treat-and-extend aflibercept in patients with eyes affected by typical neovascular age-related macula degenelation (t-AMD) or polypoidal choroidal vasculopathy (PCV), who were switched from ranibizumab....
Autores principales: | Azuma, Keiko, Asaoka, Ryo, Matsuda, Aya, Lee, Jihee, Shimizu, Kimiko, Inui, Hiroko, Murata, Hiroshi, Ogawa, Asako, Yamamoto, Motoshi, Inoue, Tatsuya, Obata, Ryo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120579/ https://www.ncbi.nlm.nih.gov/pubmed/30214143 http://dx.doi.org/10.2147/OPTH.S172115 |
Ejemplares similares
-
Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy
por: Asano, Shotaro, et al.
Publicado: (2018) -
Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy
por: Azuma, Keiko, et al.
Publicado: (2020) -
Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013) -
Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy
por: Jeon, Young-Joon, et al.
Publicado: (2021) -
Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)